

iLite® IL-12

ASSAY READY CELLS


The *iLite* IL-12 Assay Ready Cells can be used for the quantification of IL-12 or p40 inhibitor activity, or for detecting a neutralizing antibody response against such inhibitors in human serum.

IL-12, a T-cell stimulating factor, plays a critical role in the regulation of TH1 responses. As a mediator of inflammation, drugs blocking the effect of IL-12 are currently used for the treatment of autoimmune diseases, such as psoriasis and psoriatic arthritis. In addition, clinical testing of IL-12 antagonists is ongoing for a number of other inflammatory diseases.

The *iLite* IL-12 Assay Ready Cells are a genetically engineered reporter gene cell line responsive to IL-12 by specific and proportional expression of Firefly Luciferase. Normalization of cell counts and serum matrix effects is obtained by a second reporter gene, a Renilla Luciferase reporter gene construct, under the control of a constitutive promoter.

iLite IL-12 Assay Ready Cells is the perfect complement to the *iLite* IL-23 Assay Ready Cells, allowing testing for specific IL-12 inhibitory activity and screening for unwanted inhibitory activity of IL-23.

- Highly specific for IL-12 without cross reactivity to IL-23
- Can be used in combination with *iLite* IL-23 Assay Ready Cells for screening drugs for p40 inhibitory activity, or for unwanted inhibitory activity of IL-23
- Highly sensitive and ~20x fold induction



Schematic illustration of the over-expression of IL-12 receptor on the cell surface, which has no cross-reactivity with IL-23.

iLite® IL-12 Assay Ready Cells	
Product code	BM4012
Format	Assay Ready Cells
Related Products	Complementary Products
BM3044 <i>iLite</i> ® TNF-alpha Assay Ready Cells	BM4023 <i>iLite</i> ® IL-23 Assay Ready Cells
BM4050 <i>iLite</i> ® GM-CSF Assay Ready Cells	
BM3049 <i>iLite</i> ® Type I IFN Assay Ready Cells	
BM4024 <i>iLite</i> ® TLR4 Assay Ready Cells	
Application	The <i>iLite</i> IL-12 Assay Ready Cells can be used for the quantification of IL-12 or p40 inhibitor activity, or a neutralizing antibody response against such inhibitors in human serum. <ul style="list-style-type: none"> • Quantification of IL-12 inhibitor activity using <i>iLite</i> IL-12 Assay Ready Cells (E-214-GB) • Determination of neutralizing antibodies against IL-12 inhibitors using <i>iLite</i> IL-12 Assay Ready Cells (E-215-GB)
Incubation time	Drug Assays 30 min + 5 hours NAb Assays 30 min + 30 min +5 hours
Detection system	Luminescence
Availability	Research Use Only (RUO)*

*These products are intended for professional research use only. The data and results originating from using the products, should not be used either in diagnostic procedures or in human therapeutic applications.

In accepting delivery of *iLite*® Assay Ready Cells the recipient agrees not to sub-culture these cells, attempt to sub-culture them or to give them to a third party, and recipient is only to use them directly in assays. The *iLite*® cell-based products are covered by patents which are the property of Svar Life Science AB and any attempt to reproduce the delivered *iLite*® Assay Ready Cells would constitute an infringement.

Svar Life Science AB

T +46 40 53 76 00
E info@svarlifescience.com
W www.svarlifescience.com

SVAR
Answers in Life Science

Custom Assay Development

- FOR ANY BIOPHARMACEUTICAL TARGET

Svar Life Science offers the *iLite*[®] cell based reporter gene technology both as assay ready frozen cells and custom cell line development projects. Through its specificity for the drug target and a rapid test format, the *iLite* cell based assays are valuable tools during the whole drug development continuum.

The *iLite* technology is based on reporter gene technology and is used extensively by a number of major pharmaceutical and biotechnology companies for the quantification of drug potency and immunogenicity.

Benefits of the *iLite* Technology:

- Assay Ready - no culturing required
- Based on reporter gene technology
- Unrivalled specificity for the drug target
- Assessment of drug potency
- Detection of neutralizing antibodies (NAbs)
- Normalization of cell count and serum matrix effects
- Rapid test format – as simple as an ELISA
- Provides a seamless solution for accelerating drug development and reducing costs.



The possibility to custom design reporter gene cell lines and assays, using the *iLite* technology, gives customers exclusive features, such as:

- Cell lines, for your target, developed to give high specificity and no unwanted cross-reactivity
- The same cell line for quantification of drug potency and anti-drug neutralizing antibodies
- Detection of functional activity of the drug/substance during Pharmacodynamics (PD) studies, as well as during manufacturing processes
- Unique means to reduce drug discovery attrition rates and accelerate drug development by markedly reduced selection of false positive drug leads and direct comparison of relative efficacy of drug leads between individual runs
- One single unique *iLite* cell line for lead selection, CMC potency assays/bioprocessing and immunogenicity testing for registration trials through post marketing commitments
- Assay which can be run with assay ready frozen cells

Target
discovery &
validation

HTS
compound
screening

Preclinical
evaluation of
efficacy, safety PK

Manufacturing
process development
quality control

Clinical
development
phase II/III

Approval

Post market
surveillance

Innovator &
biosimilar approval

***iLite*[®]**

Screening for new
drug candidates

***iLite*[®]**

Potency assay

***iLite*[®]**

Circulating active drug levels
and NAb quantification

***iLite*[®]**

Direct comparison of
innovator & biosimilar
in one single assay